Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Declines By 6.2%

ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 10,830,000 shares, a drop of 6.2% from the February 13th total of 11,550,000 shares. Based on an average trading volume of 2,860,000 shares, the short-interest ratio is presently 3.8 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $4.50 price target on shares of ADMA Biologics in a report on Wednesday, February 8th.

Institutional Trading of ADMA Biologics

Large investors have recently made changes to their positions in the company. EWG Elevate Inc. grew its stake in shares of ADMA Biologics by 21.0% in the 3rd quarter. EWG Elevate Inc. now owns 121,000 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 21,000 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at about $85,000. Verition Fund Management LLC grew its stake in shares of ADMA Biologics by 5,380.0% in the 3rd quarter. Verition Fund Management LLC now owns 1,369,552 shares of the biotechnology company’s stock valued at $3,328,000 after buying an additional 1,344,560 shares during the period. Oppenheimer & Co. Inc. grew its stake in shares of ADMA Biologics by 18.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 200,325 shares of the biotechnology company’s stock valued at $487,000 after buying an additional 30,903 shares during the period. Finally, Viewpoint Capital Management LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at about $26,000. 71.17% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

Shares of ADMA opened at $3.22 on Wednesday. The company has a debt-to-equity ratio of 1.51, a current ratio of 5.04 and a quick ratio of 1.38. The stock has a 50-day moving average of $3.52 and a 200-day moving average of $3.17. The company has a market cap of $633.63 million, a PE ratio of -8.70 and a beta of 0.87. ADMA Biologics has a one year low of $1.43 and a one year high of $3.98.

ADMA Biologics Company Profile

(Get Rating)

ADMA Biologics, Inc operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations.